Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics

Abstract

Personalized medicine (PM) is becoming increasingly important in contemporary clinical and research scenarios. In the context of PM, pharmacogenomics and pharmacogenetics are aimed at the genetic personalization of drug response. Extrinsic and intrinsic factors may explain interindividual variability in drug response. Among such factors, age seems to specifically intervene to modulate drug response since normal developmental changes may influence the exposure-response relation. Consequently, the potential benefit of pharmacogenomics (PGx) in the paediatric population is considerable. However, many challenges still exist in incorporating PGx into clinical practice. In fact, drug prescribing in the paediatric population is often based on extrapolation from clinical trials conducted on adults as there is often a lack of paediatric data. Children are not just 'small adults', as they have their own pharmacological characteristics in terms of drug metabolism and efficacy, adverse drug reactions and toxicity. Although children might potentially benefit from such research, many ethical concerns arise at the intersection of the spheres of drug development and genetic testing. Children require particular attention because of their vulnerability both in research and the clinical applications of PGx; furthermore, children range from preterm newborns and neonates to infants and toddlers and to adolescents, thus forming a further heterogeneous target group. In this paper, we focus on some ethically relevant concerns (i.e., informed consent, stigmatization, ancillary information) that might arise as a result of the possible application of PGx tests in both paediatric practice and research.

Health in Prison: Does Penitentiary Medicine in Italy Still Exist?

“…Admitting a patient entails devising a healthcare plan and arranging, on the basis of clinical criteria and the patient's specific needs [20][21][22], for the appropriate appointments. The Prison Medical Director is responsible for planning personalized treatment programs and scheduling all necessary healthcare services, in accordance with internal processes, within the appropriate timeframe-both for basic and specialist health services.…”

<p>Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges</p>

“…Much has been written regarding genetic testing in children in general 102–111. However, fewer papers have been published specifically about the appropriateness of PGx testing in children 76,112–114. Guidelines from professional organizations focus on the benefits of testing to the child103,115 and support the use of PGx testing, particularly when the clinical utility has been demonstrated in pediatric studies 102.…”

Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs

“…Pharmacogenetics is the study of the role of genetic variability in determining inter‐individual variability in responses to pharmacological therapy (Schiavone et al ., 2017), which could potentially be used for treatment optimization in individual patients, resulting in a more targeted, more efficacious, and less harmful treatment (Loscher et al ., 2009). In general, pharmacogenetics usually refers to how variation in one single gene influences the response to a single drug.…”